Ketone Active Ingredients TRIZ Cases

Curcumin and its water-soluble conjugates lower the neutrophil-to-lymphocyte ratio, addressing a key prognosis marker across inflammatory and viral diseases.

A dual-component paeoniflorin and isoliquiritigenin formulation targets pulmonary fibrosis while reducing inflammation, collagen deposition, and cost.

Marine phospholipids form sub-500 nm emulsions that improve solubility, permeability, and GI absorption of poorly bioavailable therapeutics.

A lecithin-mediated SNEDDS combines oils, PEG 400, and nanoliposomes to stabilize quercetin and improve bioavailability.

Water-dispersible nutraceutical powders combine surfactants, oils, and release polymers to raise bioavailability while reducing dose size and frequency.

Weekly IV liposomal curcumin cycles with rest periods improve anti-proliferative activity while limiting systemic toxicity.

Combined curcumin and ursolic acid dosing addresses prostate cancer chemoprevention, with GMP protocols for bioavailability and safety.

Micron-sized clay limits absorption; nano-size montmorillonite and solvent-free loading improve bioactive uptake without toxic polymer residues.

A standardized curcumin-pomegranate blend targets low bioavailability and inflammation.

Curcumin, harmine, and isovanillin combine to kill cancer cells and stem cells while limiting recurrence and adverse effects.

This case uses silica-gel adsorption and chromatography to isolate kava Fraction B, reducing NNK-induced DNA damage and lung adenomas.

A curcumin, harmine, and isovanillin combination induces cancer cell death through synergistic action.

An oil-in-water microemulsion formulation dissolves hydrophobic active pharmaceutical ingredients for enhanced bioavailability.

Empty liposomes encapsulate QT-prolonging agents to mitigate IKr channel inhibition, preventing drug-induced QT prolongation and cardiac arrhythmias.

Nutraceutical ligands decorate nanoparticles to bind specific tissues, reducing systemic side effects while maintaining treatment efficacy.

Liposomes encapsulate QT-prolonging drugs to modulate cardiac ion channels and stabilize electrical conductivity during parenteral administration.

A sustained-release naltrexone formulation modulates plasma concentration profiles to minimize adverse effects during co-administration.

Aryl alkanones stimulate hair growth by inhibiting interleukin-17, resolving the trade-off between efficacy and adverse effects.

Inducing agents sensitize virus-infected cells to anti-viral drugs, enabling targeted elimination of infected tissue.

Isolated cyclohexenone compounds from Antrodia camphorata extracts reduce proteinuria and inhibit antinuclear antibody synthesis.

Xanthohumol buffers mitochondrial ROS to selectively inhibit pathological Ca2+ release, addressing limited clinical success of current antiarrhythmic therapies.

Enteric absorption promoters enhance oral bioavailability of plant actives like beta-sitosterol and curcumin.

Combining polykinase inhibitors and chemotherapy in micelles overcomes drug resistance while minimizing systemic toxicity.

Tailoring colchicine dosage by inhibitor strength prevents toxic accumulation while preserving efficacy in patients taking CYP3A4 or P-glycoprotein blockers.

Sequential weak and strong alkali treatments purify nepodin-containing extracts from Rumex plants.

Vitamin K reverses vascular calcification by activating matrix Gla-protein, eliminating harmful side effects from conventional cardiovascular medications.

Liposomal curcumin reduces excessive cytokine release to prevent inflammation and organ damage during infectious disease treatment.

An oral composition of curcumin, quercetin, hyaluronic acid, and chondroitin sulfate restores the urothelial mucous layer.

Formula I compounds resolve the contradiction between treatment effectiveness and safety by applying parameter changes to molecular structures.

Liposome encapsulation with polyenylphosphatidylcholine improves tetrahydrocurcumin solubility and stability in aqueous environments.

Chalcones reduce blood clotting time and increase thrombin generation without causing immunogenicity or unwanted blood clots.

Combining droxidopa with COMT or MAO inhibitors blocks rapid metabolism, extending half-life to reduce dosing frequency for orthostatic hypotension.

A dietary supplement composition combines huperzine A, Bacopa monnieri extract, acetyl-L-carnitine, and curcuminoids to support cognitive function.

Empty liposomes encapsulate drugs like crizotinib to alter pharmacokinetic profiles, reducing IKr channel inhibition and preventing QT prolongation.

Cleavable ester and carbonate linkers in the polymer backbone enable zero-order drug release over years, eliminating frequent device replacements.

A water-in-oil-in-water nanoemulsion encapsulates an oxaliplatin-bile acid ion-pair complex to enhance intestinal permeability.

Segmenting Curcuma longa extracts by polarity creates synergistic ratios that increase tumor T-cell infiltration and reduce drug resistance.

Segmented micelles with tailored shells enable targeted release in the small intestine, resolving stability issues from high active ingredient concentrations.